FDA approves Roche’s Avastin plus chemotherapy to treat women with platinum-resistant recurrent ovarian cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Food and Drug Administration (FDA) | Ovarian Cancer | Ovaries | Pharmaceuticals | Women